{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gonorrhoea/management/management/","result":{"pageContext":{"chapter":{"id":"171cfead-d784-5eab-b668-c3fe9015a93a","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field f32ee77f-1adb-4608-9356-932a4b2e5a9b --><h2>Scenario: Management</h2><!-- end field f32ee77f-1adb-4608-9356-932a4b2e5a9b -->","summary":"Covers the management of people with suspected or confirmed gonorrhoea infection.","htmlStringContent":"<!-- begin item b8b46586-0ac0-416a-9003-09115a15bc9a --><!-- begin field 2f51f377-ceb9-4fb0-804f-acbc015a4ff7 --><p>From age 13 years onwards.</p><!-- end field 2f51f377-ceb9-4fb0-804f-acbc015a4ff7 --><!-- end item b8b46586-0ac0-416a-9003-09115a15bc9a -->","topic":{"id":"8aeba2d1-9f1a-5428-a119-41fa94223706","topicId":"4b4cdbb6-97a0-4b13-a04c-d857b72bcddf","topicName":"Gonorrhoea","slug":"gonorrhoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"803822d1-16b6-5c36-b47d-9a6e8e236c06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b8d98590-b989-554f-8ccb-804279dab0d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4ac6e3b9-f31e-5367-b177-171c1cd87bd7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"41812e79-dbe3-5991-8344-05de91dff192","slug":"changes","fullItemName":"Changes"},{"id":"bbabf43d-27dd-5795-b02b-9891c7e9e7ca","slug":"update","fullItemName":"Update"}]},{"id":"cd231f06-b527-5de3-a8cb-277fd6f84587","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"858e0da7-8025-510b-ac87-1055c9b510e0","slug":"goals","fullItemName":"Goals"},{"id":"b9efda8e-7814-5479-af6b-1272844f3546","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"874bc02c-2022-584f-bc91-b99489f3ac6c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"17fcc032-43d9-5c38-b19b-e10bef0648f1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1033f77b-d5e5-5700-b7f9-f314bb1daef3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"11e8f7de-1c3f-5692-a9e4-f2c1645e1023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f889ee27-2135-5f9e-b131-fb46452febe4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"55283c6e-a75b-5deb-8827-406245e897ff","slug":"definition","fullItemName":"Definition"},{"id":"cf7e0416-d49c-57de-8063-ebf536922bcc","slug":"prevalence","fullItemName":"Prevalence"},{"id":"6c929d32-5621-5a53-9e9b-63a3e1523e20","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1196a066-1188-5938-b1d3-932dd0ffc403","slug":"complications","fullItemName":"Complications"}]},{"id":"acc7ed62-ebd4-506d-a105-4b05f6f7e38a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a9a1ae79-f8a2-59e3-a720-8207d27eee47","slug":"assessment","fullItemName":"Assessment"},{"id":"0ee9cef7-bd86-583b-9d57-f5d8f9a5d6d0","slug":"signs-symptoms-in-a-man","fullItemName":"Signs and symptoms in a man"},{"id":"9b460f20-3213-5956-896f-ccc5156c9d32","slug":"signs-symptoms-in-a-woman","fullItemName":"Signs and symptoms in a woman"},{"id":"e568c796-6f9e-5513-a973-7efca33d5b62","slug":"confirmation-of-diagnosis","fullItemName":"Confirmation of diagnosis"},{"id":"44933641-db44-5935-9459-ea8e78869d57","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"e0f6f6d2-d4a8-5801-b817-0588e8540a04","slug":"possible-sexual-abuse","fullItemName":"Possible sexual abuse"}]},{"id":"d05b0423-47bb-53df-ab5a-8730ca4d3325","fullItemName":"Management","slug":"management","subChapters":[{"id":"171cfead-d784-5eab-b668-c3fe9015a93a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"98eac615-b29a-5de3-a795-37b42615eb61","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c11c59e-3407-52b9-a870-aed88dcd9236","slug":"cephalosporins-ceftriaxone-or-cefixime","fullItemName":"Cephalosporins (ceftriaxone or cefixime)"},{"id":"af56affe-2e43-5ee7-b94a-333ead3b8efa","slug":"quinolones-ciprofloxacin-or-ofloxacin","fullItemName":"Quinolones (ciprofloxacin or ofloxacin)"},{"id":"caa85d19-223f-5ca5-ae12-313a1b2462d1","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39f7e7ee-870b-55c8-9cd9-55320d487f24","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"05886abb-50fd-51e9-b3c2-e2e99ad9b241","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bdd6db63-13f7-5183-a3a2-63b619818fb3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d44a69c-3824-5509-a756-cda3bc1bd50a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e5526ef2-c93a-595d-a0c1-8068bad91f10","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0092236d-21ec-5777-85c0-6e95f9962a15","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8791b380-0e55-5489-987e-5db590030323","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc36d12c-c9a8-5970-8b4b-74304413a1f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d05b0423-47bb-53df-ab5a-8730ca4d3325","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9b2b55a2-b25b-5b82-8372-c537d23942bb","slug":"management-in-primary-care","fullItemName":"Management in primary care","depth":3,"htmlHeader":"<!-- begin field e1896e49-d7b8-45d4-9ec9-6fc0b98ef3d6 --><h3>How should I manage a person with suspected gonorrhoea in primary care?</h3><!-- end field e1896e49-d7b8-45d4-9ec9-6fc0b98ef3d6 -->","summary":null,"htmlStringContent":"<!-- begin item f6857241-93bb-4be4-81e8-25c242b070bc --><!-- begin field 30cef64c-f43c-4442-801f-f7df4e698938 --><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/diagnosis/assessment/\">Assess</a> all people suspected of having gonorrhoea infection.</li><li>Ideally, <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#admission-referral\">refer</a> all people with confirmed or suspected gonorrhoea to a genito-urinary medicine (GUM) clinic or other local specialist sexual health service.</li><li>If these services cannot be accessed within a reasonable time, or if the person is unwilling to attend, the person can be managed in primary care if the appropriate expertise is available. <ul><li>Confirm the <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/diagnosis/confirmation-of-diagnosis/\">diagnosis</a>, preferably using nucleic acid amplification testing (NAAT), according to local protocols and procedures.</li><li>If NAAT positive for gonorrhoea, take swabs for culture before prescribing antibiotics to enable sensitivity testing and identification of resistant strains.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#treatment\">Treat</a> for gonorrhoea.</li><li>Offer screening for other sexually transmitted infections (STIs) and for HIV.</li><li>Encourage patient-led <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#partner-notification\">partner notification</a>.<ul><li>Partners should be screened for STIs and <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#treatment\">treated</a> empirically for gonorrhoea whilst awaiting results.</li></ul></li><li>Advise the person to abstain from sex until they, and any partners, have completed treatment. <ul><li>If azithromycin is used, this will be 7 days after treatment is given.</li></ul></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#follow-up\">Follow-up</a> after 1 week to verify the success of treatment.<ul><li>Test of cure is recommended for all people who have been treated for gonorrhoea.</li></ul></li><li>Provide appropriate <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#information-advice\">information and advice</a>.</li></ul></li></ul><!-- end field 30cef64c-f43c-4442-801f-f7df4e698938 --><!-- end item f6857241-93bb-4be4-81e8-25c242b070bc -->","subChapters":[{"id":"50a2eef7-8f68-5b17-9c37-1a8645fd65ef","slug":"basis-for-recommendation-0f8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d446d87f-67fe-4c32-b319-945d00d5f4ef --><h4>Basis for recommendation</h4><!-- end field d446d87f-67fe-4c32-b319-945d00d5f4ef -->","summary":null,"htmlStringContent":"<!-- begin item 0f865e6a-aca6-4ad1-845a-465b800b5449 --><!-- begin field c64b86db-2059-4701-a6c1-d78bc15a3b5e --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>], the World Health Organization (WHO) <em>Treatment of Neisseria gonorrhoea</em>e [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">WHO, 2016</a>], and the British Medical Journal (BMJ) best practice guide <em>Gonorrhoea infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BMJ, 2016</a>].</p><ul><li>The complexities of gonorrhoea management, especially contact tracing, can be challenging. As a result people should be referred promptly to specialists in genito-urinary medicine (GUM) for management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>].</li></ul><!-- end field c64b86db-2059-4701-a6c1-d78bc15a3b5e --><!-- end item 0f865e6a-aca6-4ad1-845a-465b800b5449 -->","subChapters":[]}]},{"id":"a57362c0-36a3-5f1d-b15b-7ae89551b318","slug":"treatment","fullItemName":"Treatment","depth":3,"htmlHeader":"<!-- begin field 57c400d0-2f31-4975-aa61-18369e73bae8 --><h3>How should I treat a person with gonorrhoea in primary care?</h3><!-- end field 57c400d0-2f31-4975-aa61-18369e73bae8 -->","summary":null,"htmlStringContent":"<!-- begin item 9302e030-d056-4549-9bd4-00ec5562ad32 --><!-- begin field 86742352-ce78-4ce3-912c-77729db3a4cb --><ul><li><strong>Treat gonorrhoea in primary care only if specialist services cannot be accessed within a reasonable time, or if the person is unwilling to attend despite receiving appropriate <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#information-advice\">information and advice</a>.</strong></li><li><strong>Treatment </strong>is indicated following a positive identification of <em>Neisseria gonorrhoeae. </em>For more information see the section on<em> </em><a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/diagnosis/\">Diagnosis</a>.<ul><li>Before prescribing antibiotics a culture should be taken to test for susceptibility and identify resistant strains.</li></ul></li><li><strong>Empirical treatment is indicated </strong><strong>for:</strong><ul><li>Recent sexual <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#partner-notification\">partners</a> of people with confirmed gonococcal infection. </li></ul></li><li><strong>In the unusual event that confirmed or suspected uncomplicated anogenital gonorrhoea needs to be treated in primary care, prescribe:</strong><ul><li>Ceftriaxone 1 g intramuscular (IM) injection as a single dose.<ul><li>If this regimen is unsuitable or unavailable, contact the local microbiology or genito-urinary medicine clinic for advice.</li></ul></li></ul></li><li><strong>In the unusual event that confirmed uncomplicated anogenital or pharyngeal gonorrhoea needs to be treated in primary care, and the antimicrobial susceptibility is known prior to treatment prescribe:</strong><ul><li>Ciprofloxacin 500 mg orally as a single dose.<ul><li>If this regimen is unsuitable or unavailable, contact the local microbiology or genito-urinary medicine clinic for advice.</li></ul></li></ul></li></ul><h4>Alternative regimens</h4><ul><li>These alternative regimens may be given because of allergy, needle phobia or other absolute or relative contraindications.<ul><li>Cefixime 400 mg orally as a single dose plus azithromycin 2 g orally.<ul><li>Only advisable if an intramuscular injection is contraindicated or refused by the patient.</li></ul></li><li>Gentamicin 240 mg intramuscularly as a single dose plus azithromycin 2 g orally.</li><li>Spectinomycin 2 g intramuscularly as a single dose plus azithromycin 2 g orally.<ul><li>Spectinomycin is not recommended for pharyngeal infection because of poor efficacy.</li></ul></li><li>Azithromycin 2 g as a single oral dose.<ul><li>The clinical efficacy of azithromycin does not always correlate with in vitro susceptibility testing and azithromycin resistance is high.</li></ul></li></ul></li></ul><!-- end field 86742352-ce78-4ce3-912c-77729db3a4cb --><!-- end item 9302e030-d056-4549-9bd4-00ec5562ad32 -->","subChapters":[{"id":"b09c1bb8-a641-5d6f-9c4a-65ddca26a8a5","slug":"basis-for-recommendation-3ca","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6c98d3bf-8e39-4416-a3f8-6d89571ddaef --><h4>Basis for recommendation</h4><!-- end field 6c98d3bf-8e39-4416-a3f8-6d89571ddaef -->","summary":null,"htmlStringContent":"<!-- begin item 3ca4694c-397e-414b-81af-47c083befba7 --><!-- begin field 4f9954f6-8828-48a5-8d80-3c4fd8679802 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2019</a>] a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>], the World Health Organization (WHO) <em>Treatment of Neisseria gonorrhoea</em>e [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">WHO, 2016</a>], and the British Medical Journal (BMJ) best practice guide <em>Gonorrhoea infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BMJ, 2016</a>].</p><h5>Ceftriaxone dose</h5><ul><li>BASSH guideline recommend ceftriaxone 1 g intramuscular (IM) injection as a single dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2019</a>].</li></ul><h5>Use of quinolone antibiotics</h5><ul><li>Treatment with ciprofloxacin is only recommended if <em>N. gonorrhoeae </em>is known to be quinolone sensitive, as there is a high prevalence of quinolone resistance worldwide [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2019</a>].</li></ul><!-- end field 4f9954f6-8828-48a5-8d80-3c4fd8679802 --><!-- end item 3ca4694c-397e-414b-81af-47c083befba7 -->","subChapters":[]}]},{"id":"1cb60179-bab8-5ce9-8179-bf85c97c47ac","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 8c17598d-197f-461a-8856-93c4e9fb30c3 --><h3>What treatment should I prescribe for a woman who is pregnant, or breastfeeding?</h3><!-- end field 8c17598d-197f-461a-8856-93c4e9fb30c3 -->","summary":null,"htmlStringContent":"<!-- begin item 568da080-5c35-4e31-8068-11181d38e6b7 --><!-- begin field 705fc981-02fc-4b0f-b3a0-f7e0cf8ac7e6 --><ul><li><strong>In the unusual event that confirmed or suspected uncomplicated anogenital gonorrhoea needs to be treated in primary care, </strong><strong>prescribe: </strong><ul><li>Ceftriaxone 1 g intramuscular (IM) injection as a single dose.</li><li>Do not prescribe a fluoroquinolone for a woman who is pregnant or breastfeeding. Seek specialist advice if a cephalosporin is contraindicated, for example if the woman has a true allergy to penicillin.</li></ul></li></ul><!-- end field 705fc981-02fc-4b0f-b3a0-f7e0cf8ac7e6 --><!-- end item 568da080-5c35-4e31-8068-11181d38e6b7 -->","subChapters":[{"id":"d1d81a4d-a49b-5965-8004-a4e541d9317e","slug":"basis-for-recommendation-1f5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 84a5b368-5ddd-4125-a8d5-0312f623a9fd --><h4>Basis for recommendation</h4><!-- end field 84a5b368-5ddd-4125-a8d5-0312f623a9fd -->","summary":null,"htmlStringContent":"<!-- begin item 1f520076-4b3e-4b6e-8477-27f246a8cf6a --><!-- begin field 29af5a77-c4d2-4956-a057-e5d1b9601ae2 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2019</a>], the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>], the World Health Organization (WHO) <em>Treatment of Neisseria gonorrhoea</em>e [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">WHO, 2016</a>], the British Medical Journal (BMJ) best practice guide <em>Gonorrhoea infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BMJ, 2016</a>], expert opinion in a medical textbook <em>Mandell, Douglas, and Bennett's principles and practice of infectious diseases </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">Marrazzo et al, 2010</a>], the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>] and the manufacturers' Summary of Product Characteristics for Ceftriaxone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2017</a>], Cefixime [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2015</a>], Azithromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016a</a>] and Ciprofloxacin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016b</a>]. </p><ul><li>Ceftriaxone should only be used in pregnancy if the benefits outweigh the risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]. <ul><li>Left untreated, gonorrhoea in pregnancy is associated with spontaneous abortion, premature labour, early rupture of fetal membranes, perinatal mortality, and gonococcal conjunctivitis in the newborn [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">Marrazzo et al, 2010</a>].</li></ul></li><li>Cefixime is not known to be harmful in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>].<ul><li>The recommendation that cefixime can be used as an alternative to ceftriaxone in pregnancy is based on the BASHH and the WHO guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">WHO, 2016</a>].</li></ul></li><li>Azithromycin should only be used in pregnancy or for breastfeeding women if adequate alternatives are not available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]. </li><li>Fluoroquinolones are not recommended in pregnancy or breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI, 2016b</a>].</li></ul><!-- end field 29af5a77-c4d2-4956-a057-e5d1b9601ae2 --><!-- end item 1f520076-4b3e-4b6e-8477-27f246a8cf6a -->","subChapters":[]}]},{"id":"112c2800-8712-5974-95c3-63d0fecd8dd9","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field d0f61044-9c26-4c09-80f8-a3dbeac1d408 --><h3>What information and advice should I give a person with gonorrhoea?</h3><!-- end field d0f61044-9c26-4c09-80f8-a3dbeac1d408 -->","summary":null,"htmlStringContent":"<!-- begin item 5999dae5-042c-41c9-943e-1e486d98499f --><!-- begin field f6e1a318-c7eb-4cae-b209-f8a51166737b --><ul><li>Advise the person to attend a genito-urinary medicine (GUM) clinic or other local specialist sexual health service if possible.</li><li>Discuss the long-term implications if gonorrhoea is left untreated for the health of the person and their partners. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/background-information/complications/\">complications</a>.<ul><li>Reinforce this information with clear and accurate written material where available, for example, the Family Planning Association (FPA) patient information leaflet <a href=\"http://www.fpa.org.uk/sites/default/files/gonorrhoea-information-and-advice.pdf\" data-hyperlink-id=\"65b4140a-c3f2-4ba9-9584-a93100a35a1a\">Gonorrhoea</a>. </li></ul></li><li>Provide information about the:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#treatment\">Treatment</a> of gonorrhoea and possible adverse effects.</li><li>Need for <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#partner-notification\">partner notification</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/management/management/#follow-up\">Follow up</a> required.</li></ul></li><li>Advise the person to abstain from sex until they and any partners have completed treatment. <ul><li>If azithromycin is used, this will be 7 days after treatment is given.</li></ul></li><li>Advise the person about using safer sexual practice in the future.</li></ul><!-- end field f6e1a318-c7eb-4cae-b209-f8a51166737b --><!-- end item 5999dae5-042c-41c9-943e-1e486d98499f -->","subChapters":[{"id":"a53f08cb-ad72-55b5-8593-17af0073dce4","slug":"basis-for-recommendation-3ef","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2506886c-7a89-4bda-834e-1108f4feef42 --><h4>Basis for recommendation</h4><!-- end field 2506886c-7a89-4bda-834e-1108f4feef42 -->","summary":null,"htmlStringContent":"<!-- begin item 3efd36b7-0e23-4477-812a-6e0302a110f9 --><!-- begin field 02a63832-541d-42df-9b72-8fe8215c8613 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>], and the British Medical Journal (BMJ) best practice guide <em>Gonorrhoea infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BMJ, 2016</a>].</p><!-- end field 02a63832-541d-42df-9b72-8fe8215c8613 --><!-- end item 3efd36b7-0e23-4477-812a-6e0302a110f9 -->","subChapters":[]}]},{"id":"0d6467bf-76a3-5d94-8139-267525c5cfc1","slug":"follow-up","fullItemName":"Follow-up","depth":3,"htmlHeader":"<!-- begin field 7f113f38-c3a4-4248-97ed-cad446614215 --><h3>What follow up is required for a person with gonorrhoea?</h3><!-- end field 7f113f38-c3a4-4248-97ed-cad446614215 -->","summary":null,"htmlStringContent":"<!-- begin item b87afc35-73b9-433a-ad11-680d474a4def --><!-- begin field e7c160ac-edb0-4e62-988e-2bf211c206e3 --><ul><li>Follow up all people with gonorrhoea about 1 week after treatment to:<ul><li>Confirm that the person has adhered to treatment and symptoms have resolved.</li><li>Ask about adverse reactions.</li><li>Confirm that partner notification has been carried out.</li><li>Ask about recent sexual history (and the possibility of re-infection), and reinforce advice about safe sexual practice.</li></ul></li><li>A test of cure (TOC) is recommended for all people who have been treated for gonorrhoea.<ul><li>If the person is asymptomatic, test with nucleic acid amplification testing (NAAT) where available (followed by culture if positive), at least 2 weeks after completion of treatment.</li><li>If signs or symptoms persist, test with culture, performed at least 3 days after completion of treatment.<ul><li>Consider additional testing with NAAT (for increased sensitivity) after one week if culture is negative.</li></ul></li><li>If it is not possible or practical to perform a test of cure in all people treated for gonorrhoea, prioritize the following groups:<ul><li>People with persistent signs or symptoms.</li><li>People with pharyngeal infection.</li><li>People who have been treated with anything other than the first-line recommendation.</li></ul></li></ul></li><li>All failures of antibiotics must be reported to Public Health England.</li></ul><!-- end field e7c160ac-edb0-4e62-988e-2bf211c206e3 --><!-- end item b87afc35-73b9-433a-ad11-680d474a4def -->","subChapters":[{"id":"58222b71-16cd-5ffb-93c3-5234df44ce53","slug":"basis-for-recommendation-1d8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 90dbd8a8-73bb-482d-b19c-b1ac7ee2d38a --><h4>Basis for recommendation</h4><!-- end field 90dbd8a8-73bb-482d-b19c-b1ac7ee2d38a -->","summary":null,"htmlStringContent":"<!-- begin item 1d8c899c-1e92-4882-ab71-cd0e3a9e74d7 --><!-- begin field 9eae40bf-4683-4043-926b-5710d0a1d866 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>], and the Health Protection Surveillance Centre (HPSC) <em>National guidelines for prevention and control of gonorrhoea and for minimising the impact of antimicrobial resistance in Neisseria gonorrhoea</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">HPSC, 2016</a>].</p><h5>Test of cure </h5><ul><li>Both BASHH and HPSC recommend a test of cure (TOC) for all cases of gonorrhoea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">HPSC, 2016</a>].<ul><li>Additional testing with NAAT for increased sensitivity can be considered one week after culture, if it is negative [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">HPSC, 2016</a>].</li></ul></li><li>However, the US Centers for Disease Control and Prevention (CDC) recommends that TOC is not needed for uncomplicated urogenital or rectal gonorrhoea treated with the recommended regimens [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">CDC, 2015</a>].</li></ul><!-- end field 9eae40bf-4683-4043-926b-5710d0a1d866 --><!-- end item 1d8c899c-1e92-4882-ab71-cd0e3a9e74d7 -->","subChapters":[]}]},{"id":"e6c54b21-8e60-5117-9e97-18045d16a4f6","slug":"admission-referral","fullItemName":"Admission and referral","depth":3,"htmlHeader":"<!-- begin field e8ba048b-100b-4208-8c8f-9ca472cdcdf8 --><h3>When should I refer, or admit a person with gonorrhoea?</h3><!-- end field e8ba048b-100b-4208-8c8f-9ca472cdcdf8 -->","summary":null,"htmlStringContent":"<!-- begin item fd90f16e-2c4b-46b8-8301-771f5ee7156f --><!-- begin field cefc38ea-8983-42a0-b2a8-bafeb56b3fa6 --><ul><li>Ideally, refer all people with suspected or confirmed gonorrhoea to a genito-urinary medicine (GUM) clinic or other local specialist sexual health service.</li><li><strong>Refer</strong> <strong>the following people to the appropriate speciality</strong>: <ul><li>Women who are pregnant.  </li><li>Women with suspected ascending infection. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/pelvic-inflammatory-disease/\">Pelvic inflammatory disease</a>.</li><li>People with <a class=\"topic-reference internal-reference\" href=\"/topics/gonorrhoea/background-information/complications/\">complications</a>. For example epididymitis or prostatitis in men. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/prostatitis-acute/\">Prostatitis - acute</a>.</li><li>People with conjunctival gonorrhoea.</li><li>People who have not responded to treatment.</li><li>People allergic to cephalosporins.</li></ul></li><li><strong>Admit under the following circumstances</strong>:<ul><li>People with suspected disseminated gonorrhoea (systemic symptoms may be present, such as fever, malaise, joint pain and swelling, and rash).</li><li>Women with pelvic inflammatory disease if it is severe or there are complications. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/pelvic-inflammatory-disease/\">Pelvic inflammatory disease</a>.</li></ul></li></ul><!-- end field cefc38ea-8983-42a0-b2a8-bafeb56b3fa6 --><!-- end item fd90f16e-2c4b-46b8-8301-771f5ee7156f -->","subChapters":[{"id":"33e0cf3a-3a6c-52cd-8950-7a9a33a3d088","slug":"basis-for-recommendation-60a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 27a60c4c-d705-4419-8725-5e0847b5b738 --><h4>Basis for recommendation</h4><!-- end field 27a60c4c-d705-4419-8725-5e0847b5b738 -->","summary":null,"htmlStringContent":"<!-- begin item 60ac92cf-7959-433f-9e9f-e5bccdda5366 --><!-- begin field 6734a9d8-8e29-46d9-9b4c-a96006a00d26 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>], a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>], the British Medical Journal (BMJ) best practice guide <em>Gonorrhoea infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BMJ, 2016</a>], the International Union against Sexually Transmitted Infections (IUSTI) <em>2012 European guideline on the diagnosis and treatment of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">Bignell, 2012</a>]<em>,</em> the Medical Foundation for HIV & Sexual Health (MEDFASH) <em>Standards for the management of sexually transmitted infections (STIs)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">MEDFASH, 2014</a>], and what CKS considers good clinical practice.</p><!-- end field 6734a9d8-8e29-46d9-9b4c-a96006a00d26 --><!-- end item 60ac92cf-7959-433f-9e9f-e5bccdda5366 -->","subChapters":[]}]},{"id":"1bc6cce8-35f3-5bbb-88d9-f1d2b4af2cd7","slug":"partner-notification","fullItemName":"Partner notification","depth":3,"htmlHeader":"<!-- begin field b62bbe95-24ec-47ef-bee7-40fc5e6fd69b --><h3>When and how should partners be notified?</h3><!-- end field b62bbe95-24ec-47ef-bee7-40fc5e6fd69b -->","summary":null,"htmlStringContent":"<!-- begin item efa30616-65bf-4217-b0f2-9128e4713d38 --><!-- begin field efc55477-4bd3-47bd-b6d8-5a4737a07991 --><ul><li><strong>Partner notification is essential for all people with newly diagnosed gonorrhoea. </strong>Ideally this should be done by a trained health adviser in genito-urinary medicine (GUM). If this is not possible, it may be done by a primary healthcare professional who has undergone appropriate training and has support from healthcare advisers in GUM.<ul><li>For men with symptomatic anogenital gonorrhoea, all sexual partners within the preceding 2 weeks should be notified, or their most recent partner, if this was longer than 2 weeks ago.</li><li>For all other people (women, men with asymptomatic gonorrhoea or gonorrhoea at other sites) all partners within the preceding 3 months should be notified.</li></ul></li><li>Notified partners should be offered testing and be treated empirically whilst waiting for results.</li></ul><!-- end field efc55477-4bd3-47bd-b6d8-5a4737a07991 --><!-- end item efa30616-65bf-4217-b0f2-9128e4713d38 -->","subChapters":[{"id":"12af2ac6-7bf9-5286-9652-f16b3269181d","slug":"basis-for-recommendation-9b6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f34118cb-a064-4f25-8868-e3879083e09f --><h4>Basis for recommendation</h4><!-- end field f34118cb-a064-4f25-8868-e3879083e09f -->","summary":null,"htmlStringContent":"<!-- begin item 9b668e2a-7b3d-47e9-963b-65e3ae29400a --><!-- begin field ea8db11c-1e04-4c71-9d7c-0f0881224e41 --><p>These recommendations are based on the British Association for Sexual Health and HIV (BASHH) <em>UK national guideline for the management of gonorrhoea in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>], and a joint guideline with the Royal College of General Practitioners <em>Sexually transmitted infections in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">RCGP, 2013</a>]</p><!-- end field ea8db11c-1e04-4c71-9d7c-0f0881224e41 --><!-- end item 9b668e2a-7b3d-47e9-963b-65e3ae29400a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}